South Korean Won Leads Asian FX Losses as Dollar Rises 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Bets 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
